Literature DB >> 19624592

Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer.

Karim Fizazi1, Kurt Miller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624592     DOI: 10.1111/j.1464-410X.2009.08740.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

1.  Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).

Authors:  Nancy Dawson; Heather Payne; Clare Battersby; Maria Taboada; Nick James
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-14       Impact factor: 4.553

2.  Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Authors:  Alym Abdulla; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

Review 3.  Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.

Authors:  Xuan Huang; Cindy H Chau; William D Figg
Journal:  J Hematol Oncol       Date:  2012-07-02       Impact factor: 17.388

4.  Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.

Authors:  Helen Tomkinson; John Kemp; Stuart Oliver; Helen Swaisland; Maria Taboada; Thomas Morris
Journal:  BMC Clin Pharmacol       Date:  2011-03-17

Review 5.  The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.

Authors:  Sathana Dushyanthen; Davina A F Cossigny; Gerald M Y Quan
Journal:  Cancer Growth Metastasis       Date:  2013-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.